![\"\"](\"https:\/\/www.europesays.com\/ai\/wp-content\/uploads\/2026\/08\/SinoBiological_Logo_TransparentBackground-300x52.jpg\"){kind=spacer}
<\/a><\/p>\nBridging the gap between AI design and experimental data <\/p>\n
As AI-driven innovation accelerates and antibody pipelines expand, wet-lab validation must keep pace with the speed and scale of computational discovery. Efficiently translating large numbers of antibody sequences into reliable experimental results requires high-throughput expression, parallelized testing, and structured data generation within an integrated workflow.<\/p>\n
Sino Biological\u2019s high-throughput antibody production and developability assessment platform is designed to meet this need. By integrating antibody production, developability profiling, and AI-ready data generation, the platform enables the parallel evaluation of thousands of antibody candidates within compressed timelines and can deliver high-quality data in as fast as three days.<\/p>\n
![\"SinoBiological](\"https:\/\/www.europesays.com\/ai\/wp-content\/uploads\/2026\/08\/SinoBIological_Figure_Workflow_5WideUpdated-Figure-1024x170.jpg\")
<\/p>\n
This streamlined approach helps identify developability risks earlier, supports data-driven candidate evaluation and prioritization, and generates high-quality datasets for AI model training and iterative antibody optimization\u2014accelerating the transition from computational design to experimentally validated candidates.<\/p>\n
The role of high-throughput expression in AI design<\/p>\n
As AI models become increasingly capable of de novo antibody design, efficient expression is essential for translating computationally generated sequences into testable antibodies. Sino Biological\u2019s high-throughput antibody production solution combines complementary mammalian and cell-free expression platforms to support diverse antibody formats and project requirements. This dual-platform approach enables rapid design\u2013build\u2013test\u2013learn cycles, providing experimental feedback for candidate refinement and iterative AI model optimization.<\/p>\n
Proven mammalian expression & rapid cell-free synthesis<\/p>\n
Mammalian expression systems, particularly HEK293 and CHO cells, are well established for recombinant antibody production because they support proper folding and post-translational modifications. Drawing on extensive expertise in high-throughput gene synthesis, vector construction, and optimized HEK293 and CHO transient expression, Sino Biological supports the small-scale production of high-quality recombinant antibodies across multiple formats, including VHHs, scFvs, Fabs, IgGs, bispecific antibodies, chimeric antibodies, and Fc-fusion proteins\u2014with over 100,000 projects delivered. This mammalian platform can process more than 1,000 antibodies per project, with a sequence-to-purified-antibody turnaround in as little as 10 days.<\/p>\n
Cell-free protein synthesis (CFPS) offers a rapid and flexible alternative for projects requiring greater speed or involving sequences that are challenging to express in mammalian cells. By harnessing transcriptional and translational machinery outside living cells, CFPS produces proteins in a controllable, open reaction environment while eliminating time-consuming cell culture steps, making it well suited to rapid, high-throughput workflows. Sino Biological\u2019s CFPS platform can complete expression in as fast as three hours, accelerating the conversion of AI-generated sequences into testable molecules, particularly for the ultra-fast screening of VHHs, scFvs, and mini-binders. Free from cellular viability constraints, CFPS also supports the production of toxic or difficult-to-express proteins and the incorporation of non-canonical amino acids, expanding the possibilities of AI-driven design.<\/p>\n
De-risking antibody discovery through early developability assessment<\/p>\n
Early-stage developability profiling is pivotal for de-risking the antibody discovery pipeline and streamlining candidate selection. Systematic antibody developability evaluation enables proactive identification and management of potential liabilities\u2014for example, deprioritizing candidates with desirable binding characteristics but unfavorable biophysical properties.<\/p>\n
Sino Biological provides comprehensive early-stage developability assessment, encompassing more than 20 ready-to-use assays to evaluate key attributes, including self-association (AC-SINS), hydrophobicity (HIC-HPLC\/PAIA-HIC), thermal stability (nanoDSF\/DSC), polyreactivity (BVP\/DNA\/insulin ELISA), and colloidal stability (SMAC-HPLC). Flexible assay selection and customization are available to meet specific project requirements. Sino Biological delivers structured, AI-ready datasets that provide a multidimensional view of antibody developability profiles, enabling early risk identification and accelerating AI-driven discovery workflows.<\/p>\n
\u00a0<\/p>\n
![\"SinoBIological](\"https:\/\/www.europesays.com\/ai\/wp-content\/uploads\/2026\/08\/SinoBIological_QR-Code_at-the-end-300x300.jpg\")
To learn more, visit: